Back

Single-cell transcriptomics reveal individual and synergistic effects of Trisomy 21 and GATA1s on hematopoiesis

Takasaki, K.; Wafula, E. K.; Kumar, S. S.; Smith, D.; Sit, Y. T.; Gagne, A. L.; French, D. L.; Thom, C. S.; Chou, S. T.

2024-10-31 molecular biology
10.1101/2024.05.24.595827 bioRxiv
Show abstract

Trisomy 21 (T21), or Down syndrome (DS), is associated with baseline macrocytic erythrocytosis, thrombocytopenia, and neutrophilia, as well as transient abnormal myelopoiesis (TAM) and myeloid leukemia of DS (ML-DS). TAM and ML-DS blasts both arise from an aberrant megakaryocyte-erythroid progenitor and exclusively express GATA1s, the truncated isoform of GATA1, while germline GATA1s mutations in a non-T21 context lead to congenital cytopenia(s) without a leukemic predisposition. This suggests that T21 and GATA1s both perturb hematopoiesis in multipotent progenitors, but studying their individual effects is challenging due to limited access to relevant human progenitor populations. To dissect individual developmental impacts, we used single-cell RNA-sequencing to interrogate hematopoietic progenitor cells (HPCs) from isogenic human induced pluripotent stem cells differing only by chromosome 21 and/or GATA1 status. The transcriptomes of these HPCs revealed significant heterogeneity and lineage skew dictated by T21 and/or GATA1s. T21 and GATA1s each disrupted temporal regulation of lineage-specific transcriptional programs and specifically perturbed cell cycle genes. Trajectory inference revealed that GATA1s nearly eliminated erythropoiesis, slowed MK maturation, and promoted myelopoiesis in the euploid context, while in T21 cells, GATA1s competed with the enhanced erythropoiesis and impaired megakaryopoiesis driven by T21 to promote production of immature erythrocytes, MKs, and myeloid cells. The use of isogenic cells revealed distinct transcriptional programs that can be attributed specifically to T21 and GATA1s, and how they independently and synergistically result in HPC proliferation at the expense of maturation, consistent with a pro-leukemic phenotype.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
HemaSphere
16 papers in training set
Top 0.1%
19.1%
2
Blood
74 papers in training set
Top 0.2%
8.1%
3
Stem Cell Reports
130 papers in training set
Top 0.3%
8.1%
4
Blood Advances
62 papers in training set
Top 0.2%
7.5%
5
Nature Communications
5641 papers in training set
Top 28%
5.3%
6
Experimental Hematology
11 papers in training set
Top 0.1%
4.2%
50% of probability mass above
7
Stem Cells
31 papers in training set
Top 0.2%
3.5%
8
Scientific Reports
3612 papers in training set
Top 31%
3.3%
9
Cell Reports
1498 papers in training set
Top 11%
3.3%
10
Haematologica
25 papers in training set
Top 0.2%
3.3%
11
eLife
5828 papers in training set
Top 34%
3.2%
12
Science Advances
1243 papers in training set
Top 14%
2.5%
13
PLOS ONE
5266 papers in training set
Top 51%
1.5%
14
Journal of Hematology & Oncology
10 papers in training set
Top 0.2%
1.2%
15
Stem Cell Research & Therapy
30 papers in training set
Top 0.5%
1.1%
16
Frontiers in Immunology
638 papers in training set
Top 8%
1.0%
17
iScience
1154 papers in training set
Top 33%
0.9%
18
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.6%
0.9%
19
Leukemia
42 papers in training set
Top 0.8%
0.6%
20
Journal of Thrombosis and Haemostasis
32 papers in training set
Top 0.5%
0.6%
21
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 43%
0.6%
22
Journal of Biological Chemistry
690 papers in training set
Top 10%
0.6%
23
Communications Biology
993 papers in training set
Top 33%
0.6%